Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 13/1/2021
SIETES contiene 93213 citas

 
 
 1 a 20 de 172 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original
Anónimo. Mechanism target of rapamycin (mTOR): future therapeutic opportunities. Br J Clin Pharmacol 2016;82:1151-403. [Ref.ID 100930]
2. Cita con resumen
Anónimo. Consolidations de fracture retardées par des médicaments. Prescrire 2015;35:507-12. [Ref.ID 99440]
3. Cita con resumen
García E, Buenasmañanas D, Martín C, Rojas R. Neumonitis intersticial asociada a sirolimus en un paciente receptor de un trasplante de progenitores hematopoyéticos. Med Clin (Barc) 2015;145:21-3. [Ref.ID 99321]
4. Cita con resumen
Knoll G, Kokolo M, Mallick R, Beck A, Buenaventura C, Ducharme R, Barsoum R, Bernasconi C, Blydt-Hansen TD, Ekbergh H, Felipe CR, Firth J, Gallon L, Gelens M, Glotz D, Gossmann J, Guba M, Morsy AA, Salgo R, Scheuermann EH, Tedesco-Silva H, Vitko S, Watson C, Fergusson DA. Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ 2014;349:g6679. [Ref.ID 98345]
5.Tiene citas relacionadas Cita con resumen
Maeng M, Tilsted HH, Jensen LO, Krusell LR, Kaltoft A, Kelbaek H, Viladsen AB, Ravkilde J, Hansen KN, Christiansen EH, Aaroe J, Jensen JS, Kristensen SD, Botker HE, Thuesen L, Madsen M, Thayssen P, Sorensen HT, Lassen JF. Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial. Lancet 2014;383:2047-56. [Ref.ID 97702]
6.Tiene citas relacionadas
Stefanini GG, Windecker S. Stent performance: never too late to sort it out. Lancet 2014;383:2024-6. [Ref.ID 97701]
7. Cita con resumen
Anónimo. Évérolimus après transplantation hépatique. Prescrire 2013;33:730. [Ref.ID 96230]
8. Cita con resumen
Bailey DG, Dresser G, Arnold MO. Grapefruit-medication interactions: forbidden fruit or avoidable consequences? . Can Med Assoc J 2013;185:309-16. [Ref.ID 94799]
9. Cita con resumen
Stefanini GG, Homes Jr DR. Drug therapy: drug-eluting coronary-artery stents. N Engl J Med 2013;368:254-65. [Ref.ID 94789]
10. Cita con resumen
Pirmohamed M. Drug-grapefruit juice interactions. BMJ 2013;346:9. [Ref.ID 94758]
11. Cita con resumen
Euvrard S, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I, Broeders N, del Marmol V, Chatelet V, Dompmartin A, Kessler M, Serra AL, Hofbauer GP, Pouteil-Noble C, Campistol JM, Kanitakis J, Rouox AS, Decullier E, Dantal J, TUMORAPA Study Group. Sirolimus and secondary skin cancer prevention in kidney transplantation. N Engl J Med 2012;367:329-39. [Ref.ID 93498]
12. Cita con resumen
Hampton T. Drug linked with diabetes. JAMA 2012;307:2247. [Ref.ID 93180]
14.Tiene citas relacionadas Cita con resumen
De Luca G, Dirksen MT, Spaulding C, Kelbaek H, Schalij M, Thuesen L, van der Hoeven B, Vink MA, Kaiser C, Musto C, Chechi T, Spaziani G, Díaz de la Llera LS, Pasceri V, Di Lorenzo E, Violini R, Cortese G, Suryapranata H, Stone GW, for the Drug-Eluting Stent in Primary Angioplasty (DESERT) Cooperation. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Arch Intern Med 2012;172:611-21. [Ref.ID 92786]
15.Tiene citas relacionadas Cita con resumen
Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D'Ascenzo F, Kimura T, Briguori C, Sabaté M, Kim H-S, De Waha A, Kedhi E, Smits PC, Kaiser C, Sardella G, Marullo A, Kirtane AJ, Leon MB, Stone GW. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012;379:1393-402. [Ref.ID 92725]
16.Tiene citas relacionadas
Ormiston JA, Webster MW. Stent thrombosis: has the firestorm been extinguished?. Lancet 2012;379:1368-9. [Ref.ID 92723]
17. Cita con resumen
Montastruc J-L. Médicaments déterminant HTA : du nouveau !. BIP31.fr 2012;19:19-20. [Ref.ID 92664]
18. Cita con resumen
Anónimo. Medicines interactions: the role of P-glycoprotein. Prescriber Update 2011;32:21-2. [Ref.ID 91143]
19. Cita con resumen
McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch III JP, Goldberg HJ, Young LR, Kinder BW, Downey GP, Sullivan EJ, Colby TV, McKay RT, Cohen MM, Korbee L, Taveira Da Silva AM, Lee H-S, Krischer JP, Trapnell BC, for the National Institutes of Health Rare Lung Diseases Consortium and the MILES Trial Group. Efficacy and safety of sirolimus in lymphangioleimyomatosis. N Engl J Med 2011;364:1595-606. [Ref.ID 90556]
20.Tiene citas relacionadas
Kaiser C, Pfisterer M. Drug-eluting or bare-metal stents in large coronary arteries. Author/editor response. N Engl J Med 2011;364:1180. [Ref.ID 90518]
Seleccionar todas
 
 1 a 20 de 172 siguiente >>